What do you mean by IRCTC

Discussion on Gilead Sciences WKN: 885823 ISIN: US3755581036 Abbreviation: GILD Forum: Community

Mumbai | New Delhi: Gilead Science Inc has announced that it is building a global consortium of pharmaceutical and chemical manufacturers in North America, Europe and Asia to expand the global capacity and production of remdesivir, the drug that has shown a reduction in recovery time for coronavirus patients Has . In India, according to the people familiar with the development, the company is in talks with Dr. Reddys Laboratories, Cipla, Jubilant Lifesciences, and Strides Pharmaceuticals to grant them voluntary licenses to manufacture the drug. A Jubilant official declined to comment. "We do not comment on market speculation," said a spokesman for the Dr. Reddy's Laboratories. The other two companies did not answer ET's questions. "In the case of regulatory action, we are discussing with various groups how we could bring remdesivir to developing countries," Venus Tsang, senior director of public affairs at Asia-Gilead, told ET in a statement emailed to it. The company is aware of proposals that manufacturers should license their intellectual property under various pooled agreements. "We will carefully consider whether these proposals will benefit the amount of supply or the speed at which they are being made available once we understand the details of such proposals," Tsang said.  Preferred Model Tsang added that Gilead would be looking at ways to potentially make the treatment available to a wider patient population by exploring other formulations and routes of administration. Remdesivir is currently administered to patients by intravenous infusion. Remdesivir, one of the most watched drugs used to treat coronavirus, received emergency approval from the U.S. Food and Drug Administration (USFDA) last week. This makes it the first approved therapy for the virus that paralyzed life in large parts of the world, causing the deaths of nearly a quarter of a million people. The USFDA approval is based on experimental results that showed the drug reduced recovery time from 10 to 5 days in moderate-weight patients. However, the data on patient mortality remained clinically insignificant. "We are aware that Gilead is discussing voluntary licensing with Indian generic drug companies," said a government official. The US drug maker had similar partnerships with Indian pharmaceutical companies four years ago when it launched its novel hepatitis C therapy called sofosbuvir. Voluntary licensing is Gilead's preferred model in developing countries. Legal experts believe that in a pandemic situation, pharmaceutical companies prefer to make their treatment available instead of running the risk of countries resorting to mandatory licensing to allow third party production without the consent of the patent holder. “In a pandemic there is a risk that India will invoke non-commercial use by the government that is TRIPS compliant. The only way to overcome this potential risk is to have Gilead issue voluntary licenses to make the drug widely available, ”said Murali Neelakantan, a healthcare attorney. It is imperative that countries work together to ensure adequate supplies to people around the world, and we look forward to working together, Gilead said. The company has not yet announced the price of the drug. (For all the business news, breaking news, and the latest news in the Economic Times.) OPINION READ COMMENTS COMMENT POSTS PARTS THIS ARTICLE READ MORE ABOUT REMDESIVIR US FOOD AND DRUG DISPOSAL INDIAN PHARMA DR. REDDY SCIPLA DR. REDDY SCIPLA DR. REDDY SCIPLA In the Spotlight Catalyzing ET Virtual: The Role of Brand Communication During a Lockdown  Related News Gilead's Antiviral Drug Remdesivir Flops In First Attempt  Covid-19 Cure: The Story Of Antiviral Medicine Remdesivir  Lancet Study Shows No Significant Clinical Benefits Of The Antiviral Drug Remdesivir  Remdesivir shows promise against COVID-19 but more trials are needed: Scientists  Most Read News India offers twice as much land to companies leaving China as Luxembourg  Colonel Ashutosh Sharma, martyred in Handwara, was im 13th attempt to join the Indian army  IT hardware body marks Aarogya Setu order  The Delhi government charges a special 70% corona fee for the MRP of liquor bottles ürzt Sensex crashes 2.0 guidelines in Delhi How to check your income tax slab insurance EPFO portal login Tax sa ving deadline extended PAN Aadhaar linking deadline extended More from our network इकनॉमिक टाइम्स ઈકોનોમિક ટાઈમ્સ Pune Mirror Bangalore Mirror Ahmedabad Mirror ItsMyAscent Education Times Brand Capital Mumbai Mirror Times Now Indiatimes महाराष्ट्र टाइम्स ವಿಜಯ ಕರ್ನಾಟಕ Go Green AdAge India Eisamay IGN India Samay Times of India Samayam Tamil Samayam Telugu Miss Kyra Bombay Times Filmipop Games App MX Player DOWNLOAD ET APP FOLLOW US ON Terms of Use & Grievance Redressal Policy Privacy Policy | Feedback | Turn off personalized ads and delete data Copyright © 2020 Bennett Coleman & Co. All rights reserved. Driven by Indiatimes.